EZH2 and B-cell non-Hodgkin lymphoma: While EZH2 inhibitors are already being evaluated in phase 1 and 2 clinical trials in different solid tumors and B cell lymphoma [15], not only in MDS [16] but also in AML, EZH2 is increasingly under study as a potential therapeutic target.